Search results
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by a progressive increase in pulmonary artery pressure and pulmonary vascular resistance, leading to right ventricular failure and death.1 The recent World Health Organization (WHO) classification designates PAH as Group I and includes idiopathic PAH (IPAH)—formerly known as primary pulmonary hypertension (PPH)…
View more
Added:
1 year ago
Stay updated on the AHA 22 late-breaking data!
In this information packed episode of the View from the Thoraxcenter, hosts Dr Joost Daemen and Prof Nicolas Van Mieghem (Thoraxcenter, Erasmus MC, Rotterdam, NL) analyse the data from 10 late-breaking trials presented at the Scientific Sessions.
What are the key take-aways from AHA 22? What are the most promising findings? How should we understand…
View more
Added:
1 year ago
AHA 2022 — Dr Markus P Schlaich (University of Western Australia, AU) joins us to discuss the key findings from the PRECISION trial (NCT03541174).This randomized, phase 3 study assessed the sustained blood pressure lowering effect of a dual endothelin receptor antagonist, aprocitentan (Idorsia Pharmaceuticals Ltd.) in resistant hypertension.
Presented first at AHA 22, the trial showed that…
View more
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a progressive and debilitating disease with limited treatment options. Although some patients do well with calcium channel blockers, most ultimately need more advanced therapy, such as prostanoids. Recently, a new class of therapeutic agents has been developed to treat these patients: the endothelin receptor antagonists (ERAs). Although they are not…
View more
Start date:
Nov 15, 2022
View more
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a disorder of the pulmonary circulation in which elevated pressure in the pulmonary vascular circuit, when severe, can lead to right heart failure and eventually cause death. The last three decades have seen significant advances in our understanding of this group of disorders and, with this understanding, the development of novel therapies to assist in…
View more
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a disorder of the pulmonary circulation in which elevated pressure in the pulmonary vascular circuit, when severe, can lead to right heart failure and eventually cause death. The last three decades have seen significant advances in our understanding of this group of disorders and, with this understanding, the development of novel therapies to assist in…
View more
Added:
3 years ago
Pulmonary arterial hypertension (PAH) has an estimated prevalence of 15–25 cases/million population.1 This chronic, progressive disease is defined by a mean pulmonary arterial pressure >25mmHg in conjunction with normal pulmonary capillary wedge pressure <15mmHg.2 The disease is characterized by increased vascular resistance of the pulmonary microvasculature, ultimately resulting in right…
View more
Added:
3 years ago
Pulmonary hypertension is classified into five groups by the World Health Organization (WHO). Group 1, pulmonary arterial hypertension (PAH), is a progressive disease characterized by an elevation in pulmonary arterial pressure and pulmonary vascular resistance that may progress to right heart dysfunction and failure.1 PAH is defined as a mean pulmonary artery pressure (mPAP) ≥25 mmHg at rest,…
View more
Added:
3 years ago
The recent World Health Organization (WHO) classification designates PAH as Group I and includes idiopathic PAH (IPAH), formally known as primary pulmonary hypertension (PPH), familial PAH, and PAH associated with various systemic disorders such as collagen vascular diseases, congenital systemic-to-pulmonary shunts, portal hypertension, anorexigen use, and human immunodeficiency virus (HIV)…
View more
